Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.

A multicenter French study led by Rennes University Hospital reports potential benefits of glucagon-like peptide-1 receptor ...

Serena Williams has revealed that she's taking a GLP-1 injectable weight loss treatment, in addition to her health regimen.

Most people have likely heard about the new weight-loss and diabetes management drugs called Ozempic and Mounjaro, which are ...

Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing cancer risk among patients with obesity, particularly for endometrial, ovarian, and meningioma cancers.

This retrospective cohort study found that taking glucagon-like peptide-1 receptor agonists (GLP-1RAs) was associated with a reduced overall risk of cancer, including lower risks of endometrial, ...

GLP-1 receptor agonists show promise in treating hidradenitis suppurativa, offering significant symptom relief and improved ...

Longer-term studies will be needed to track whether per-patient costs might drop over time with continued use of the meds.

New research reveals that GLP-1 receptor agonists significantly lower mortality risk in older cancer patients with type 2 ...

Serena Williams revealed how she turned her health around with the help of a GLP-1 medication after she struggled to lose ...

Tennis legend Serena Williams has sparked conversations around fitness and health after reports of her weight loss journey ...

Uagnda's Dei BioPharma Ltd has announced that the U.S. Food and Drug Administration has accepted the development plan for two of its novel biological drugs, liraglutide and semaglutide, which are used ...